Clinical Outcomes of Respiratory Syncytial Virus Infection Among Pediatric Immunocompromised Hosts
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31484 ↗At a glance
Journal article in Pediatric Blood & Cancer, 2025. Written by Hailey S Ross and 8 co-authors. Institution: Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Major MEDLINE topics: Respiratory Syncytial Virus Infections, Immunocompromised Host, Respiratory Syncytial Virus, Human, Respiratory Tract Infections. Cited 15 times so far (Crossref); 32 references. Funded by: American Lebanese Syrian-Associated Charities.
Abstract (original language)
Background
Pediatric immunocompromised patients are at an increased risk of severe respiratory syncytial virus (RSV) infection. Here, we aimed to describe the clinical course and outcomes of RSV infection in immunocompromised children.
Methods
This single‐center study at St. Jude Children's Research Hospital involved immunocompromised children ≤21 years old with a positive RSV clinical test from 2007 to 2019. Demographic and clinical characteristics, laboratory values, treatment delays for underlying conditions, and outcomes were gathered from electronic medical records. Multivariate models identified risk factors predictive of severe RSV‐lower respiratory tract infection (LRTI).
Results
A total of 391 patients, predominantly children over 2 years old (median age: 5), were included in the study. Acute lymphoblastic leukemia (ALL) was the most prevalent underlying disease. Most patients (85.7%) exhibited upper respiratory tract infections, while approximately 6% progressed to LRTIs. Over half of the patients (58.8%) required hospitalization, and one‐third experienced modifications or delays in their underlying disease treatment due to RSV infection. Severe RSV infections were observed in 15.9% of patients. All‐cause mortality was 2.6%, with 0.7% of deaths attributed to RSV.
Conclusions
One‐third of patients experienced a delay in treatment for their underlying disease due to RSV infection, a phenomenon not well understood but potentially significant. Many immunocompromised children with RSV require hospitalization, including those over 2 years old. RSV imposes a significant burden on immunocompromised children of all ages, affecting their cancer treatment plans both directly and indirectly.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
ORCID profiles: Asuncion Mejias, Diego R Hijano
Funding
- American Lebanese Syrian-Associated Charities
Cite
APA
Ross, H. S., Dallas, R. H., Ferrolino, J. A., Johnson, M. B., Allison, K. J., Cross, S. J., Hayden, R. T., Mejias, A., & Hijano, D. R. (2025). Clinical Outcomes of Respiratory Syncytial Virus Infection Among Pediatric Immunocompromised Hosts. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31484
Vancouver
Ross HS, Dallas RH, Ferrolino JA, Johnson MB, Allison KJ, Cross SJ, et al. Clinical Outcomes of Respiratory Syncytial Virus Infection Among Pediatric Immunocompromised Hosts. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31484
BibTeX
@article{Ross2025,
author = {Ross, Hailey S and Dallas, Ronald H and Ferrolino, Jose A and Johnson, Madeline B and Allison, Kim J and Cross, Shane J and Hayden, Randall T and Mejias, Asuncion and Hijano, Diego R},
title = {Clinical Outcomes of Respiratory Syncytial Virus Infection Among Pediatric Immunocompromised Hosts},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31484}
}
EUVIMED